佰仁医疗
(688198)
| 流通市值：161.46亿 | | | 总市值：161.46亿 |
| 流通股本：1.37亿 | | | 总股本：1.37亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 76,265,199.91 | 370,638,328.12 | 257,391,045.85 | 167,644,027.47 |
| 营业收入 | 76,265,199.91 | 370,638,328.12 | 257,391,045.85 | 167,644,027.47 |
| 二、营业总成本 | 76,377,849.14 | 270,457,757.53 | 197,201,545.85 | 131,358,049.48 |
| 营业成本 | 8,172,523.24 | 37,638,664.42 | 26,566,403.3 | 18,456,133.53 |
| 税金及附加 | 530,800.66 | 2,108,906.85 | 1,597,322.64 | 1,046,964.5 |
| 销售费用 | 23,598,832.35 | 100,732,858.27 | 83,321,300.8 | 57,014,392.05 |
| 管理费用 | 8,196,499.21 | 31,235,197.3 | 23,008,897.89 | 15,873,995.46 |
| 研发费用 | 40,109,397.09 | 98,812,481.99 | 63,084,473.96 | 39,364,638.05 |
| 财务费用 | -4,230,203.41 | -70,351.3 | -376,852.74 | -398,074.11 |
| 其中:利息费用 | 121,113.23 | 414,739.89 | 240,921.46 | 127,672.19 |
| 其中:利息收入 | 4,402,041.43 | 786,658.69 | 622,217.63 | 457,783.85 |
| 加:公允价值变动收益 | 418,590.33 | 999,386.3 | 3,253,399.42 | 1,979,955.3 |
| 加:投资收益 | 2,803,910.07 | 16,874,958.19 | 7,835,701.22 | 5,651,947.05 |
| 资产处置收益 | - | 56,582.61 | 49,789.44 | 49,789.44 |
| 信用减值损失(新) | 38,448.78 | -1,485,484.16 | -586,920.25 | 188,252.72 |
| 其他收益 | 2,127,552.96 | 4,193,114.63 | 3,836,560.55 | 3,594,480.27 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 5,275,852.91 | 120,819,128.16 | 74,578,030.38 | 47,750,402.77 |
| 加:营业外收入 | 36,144.05 | 306,987.84 | 33,263.36 | 33,263.36 |
| 减:营业外支出 | 500,335.66 | 1,108,778.26 | 607,291.42 | 606,213.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,811,661.3 | 120,017,337.74 | 74,004,002.32 | 47,177,452.95 |
| 减:所得税费用 | 915,400.85 | 10,608,511.9 | 5,537,973.93 | 3,544,371.66 |
| 六、净利润 | 3,896,260.45 | 109,408,825.84 | 68,466,028.39 | 43,633,081.29 |
| 持续经营净利润 | 3,896,260.45 | 109,408,825.84 | 68,466,028.39 | 43,633,081.29 |
| 归属于母公司股东的净利润 | 8,319,805.58 | 115,206,553.74 | 70,346,167.91 | 44,220,129.4 |
| 少数股东损益 | -4,423,545.13 | -5,797,727.9 | -1,880,139.52 | -587,048.11 |
| (一)基本每股收益 | 0.06 | 0.85 | 0.52 | 0.33 |
| (二)稀释每股收益 | 0.06 | 0.84 | 0.51 | 0.32 |
| 八、其他综合收益 | 1,391,822.86 | 1,285,985.48 | 1,811,918.09 | 2,205,469.12 |
| 归属于母公司股东的其他综合收益 | 1,391,822.86 | 1,285,985.48 | 1,811,918.09 | 2,205,469.12 |
| 九、综合收益总额 | 5,288,083.31 | 110,694,811.32 | 70,277,946.48 | 45,838,550.41 |
| 归属于母公司股东的综合收益总额 | 9,711,628.44 | 116,492,539.22 | 72,158,086 | 46,425,598.52 |
| 归属于少数股东的综合收益总额 | -4,423,545.13 | -5,797,727.9 | -1,880,139.52 | -587,048.11 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-31 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |